Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) just unveiled an announcement.
Shandong Xinhua Pharmaceutical Company Limited has announced that it has received a Drug Registration Certificate for its Pregabalin oral solution from the National Medical Products Administration. This approval marks a significant step for the company, allowing it to produce and market the drug, which is used in the treatment of postherpetic neuralgia, fibromyalgia, and partial seizures, thereby potentially enhancing its market position and expanding its product offerings.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, specializing in the production of a range of pharmaceutical products. The company focuses on the development and manufacturing of prescription drugs, with a market emphasis on domestic production.
YTD Price Performance: -6.37%
Average Trading Volume: 2,139,988
Technical Sentiment Signal: Hold
Current Market Cap: HK$8.49B
See more insights into 0719 stock on TipRanks’ Stock Analysis page.